Drug Trial Radar · NCT02299414
Chronic Hypertension and Pregnancy (CHAP) Project
Last checked: Nov 19, 2026Latest source record: May 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,408
Actual
Start
Jun 2015
Primary completion
Apr 1, 2022
Study completion Dec 16, 2022
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Columbia University; Drexel University College of Medicine; Rutgers, The State University of New Jersey; Lehigh Valley Hospital; Saint Peters University Hospital; Christiana Care Health Services; Washington University School of Medicine; Duke University; University of Texas Southwestern Medical Center; The University of Texas Health Science Center, Houston; Stanford University; University of Pennsylvania; The University of Texas Medical Branch, Galveston; University of Utah; Intermountain Health Care, Inc.; University of California, San Francisco; Johns Hopkins University; University of Pittsburgh; Ochsner Health System; University of North Carolina, Chapel Hill; National Heart, Lung, and Blood Institute (NHLBI); WakeMed Health and Hospitals; San Francisco General Hospital; McKay-Dee Hospital; Winthrop University Hospital; New York Hospital Queens; Latter Day Saints Hospital; Lyndon B Johnson General Hospital; Virtua Medical Group; Duke Regional Hospital; Utah Valley Regional Medical Center; Northwestern University; Women and Infants Hospital of Rhode Island; Baylor College of Medicine; Case Western/Metro Health; Ohio State University; University of Iowa; University of California, San Diego; Indiana University; Meriter Foundation; Weill Medical College of Cornell University; University of Oklahoma; Medical University of South Carolina; Beaumont Hospital; University of Colorado, Denver; University of Kansas Medical Center; Denver Health and Hospital Authority; Gundersen Health System; Wake Forest University Health Sciences; Oregon Health and Science University; Medical College of Wisconsin; Temple University; New Jersey Medical School; University of South Alabama; Vanderbilt University; University of Arkansas; Emory University; St. Luke's Hospital and Health Network, Pennsylvania; The Cleveland Clinic; University of Tennessee; TriHealth Inc.; Tulane University; Yale University; Arrowhead Regional Medical Center; Geisinger Clinic; Miami Valley Hospital
- First posted
- Nov 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether a blood pressure treatment strategy during pregnancy to achieve targets that are recommended for non-pregnant reproductive-age adults (\<140/90 mmHg) compared ACOG- recommended standard during pregnancy (no treatment unless BP is severe) is effective and safe.
Conditions
- Hypertension
Interventions
Anti-hypertensive therapyDrug
1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
No anti-hypertensive therapy (unless BP is severe)Other
Treatment will not be started if blood pressure remains \<160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite Adverse Perinatal OutcomeTime frame: Up to 2 weeks postpartum for preeclampsia or 90 days for neonatal death
- Small for Gestational Age (Safety)Time frame: Until delivery
Locations
72 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham, Clinical Coordinating Center
Birmingham, Alabama
University of Alabama at Birmingham, Data Coordinating Center
Birmingham, Alabama
University of South Alabama
Mobile, Alabama
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Arrowhead Regional Medical Center
Colton, California
University of California, San Diego
San Diego, California
General Hospital of San Francisco
San Francisco, California
University of California San Francisco
San Francisco, California
Stanford University
Stanford, California
University of Colorado
Boulder, Colorado
Denver Health
Denver, Colorado
Yale University
New Haven, Connecticut
Christiana Care Health Services
Newark, Delaware
University of South Florida
Tampa, Florida
Emory University
Atlanta, Georgia
Northwestern
Evanston, Illinois
Indiana University
Bloomington, Indiana
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center
Lawrence, Kansas
University of Kentucky
Lexington, Kentucky
Tulane
New Orleans, Louisiana
Ochsner Health System/Medical Center
New Orleans, Louisiana
Beaumont Hospital
Royal Oak, Michigan
University of Mississippi Medical College
Jackson, Mississippi
Washington University
St Louis, Missouri
Robert Wood Johnson Medical School
New Brunswick, New Jersey
St. Peters University Hospital
New Brunswick, New Jersey
New Jersey Medical School
Newark, New Jersey
Virtua Medical Group
Sewell, New Jersey
New York Presbyterian Queens
Flushing, New York
Winthrop University Hospital
Mineola, New York
Columbia University
New York, New York
Weill Cornell
New York, New York
University of North Carolina
Chapel Hill, North Carolina
Duke Regional Medical Center
Durham, North Carolina
Duke University
Durham, North Carolina
WakeMed
Raleigh, North Carolina
TriHealth, Inc
Cincinnati, Ohio
Case Western/Metro Health
Cleveland, Ohio
Cleveland Clinic Fairview
Cleveland, Ohio
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.